Latent Viral Reservoir

Latent Viral Reservoir refers to populations of infected cells that harbour viral genetic material in a dormant or transcriptionally silent state, enabling viruses to persist despite immune clearance and antiviral therapy. This concept is most clinically significant in chronic viral infections such as HIV, where latent reservoirs remain the primary barrier to cure. These reservoirs can reactivate under certain conditions, leading to viral rebound if therapy is stopped.

The biopharmaceutical industry targets latent viral reservoirs through advanced therapeutic strategies aimed at achieving functional cure or eradication. Approaches include latency-reversing agents that reactivate dormant virus for immune clearance, immune-based therapies enhancing cytotoxic responses, broadly neutralising antibodies, and gene editing technologies that disrupt viral DNA or host entry pathways. Clinical development is challenging due to the need for sensitive assays to quantify reservoir size, the complexity of tissue compartmentalisation, and ethical constraints of treatment interruption studies. Regulatory pathways require strong safety justification because interventions may involve immune activation or genetic modification. As antiviral innovation advances, latent reservoir research continues shaping next-generation curative strategies and long-term disease control frameworks.